Antibody-based proteomics: fast-tracking molecular diagnostics in oncology

  title={Antibody-based proteomics: fast-tracking molecular diagnostics in oncology},
  author={Donal J. Brennan and Darran P. O'Connor and Elton Rexhepaj and Fredrik Pont{\'e}n and William M. Gallagher},
  journal={Nature Reviews Cancer},
The effective implementation of personalized cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision making. Antibody-based proteomics occupies a pivotal space in the cancer biomarker discovery and validation pipeline, facilitating the high-throughput evaluation of candidate markers. Although the clinical utility of these emerging technologies remains to be established, the traditional use of antibodies as affinity… 
Biomarker Discovery in Cancer and Autoimmunity using an Affinity Proteomics Platform - a Tool for Personalized Medicine
This thesis demonstrated the feasibility of using antibody microarrays for identification of protein biomarker signatures in both cancer and auto-immunity, and identified plasma protein patterns that potentially could be used for stratification of heterogeneous patient groups into sub-groups of high or low risk of having prostate cancer.
Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer
  • L. Sempere
  • Biology
    Expert review of molecular diagnostics
  • 2011
The challenges and opportunities for integration of miRNA-based assays in the clinical toolkit to improve care and management of patients afflicted with solid tumors will be discussed.
Proteomic approaches to the discovery of cancer biomarkers for early detection and personalized medicine.
The proteomic platforms that are currently being used for cancer biomarker discovery are introduced, and examples of novel cancer biomarkers that were identified with each proteomic technology are described.
Tissue and plasma proteomics for early stage cancer detection.
The relative advantages and disadvantages of the most frequently used techniques for cancer diagnosis, prognosis, treatment and surveillance are outlined, concentrating on the latest advances and application of tissue and plasma proteomics for novel cancer biomarker discovery and disease surveillance.
Application of molecular technologies for phosphoproteomic analysis of clinical samples
This review provides a description of the main proteomic platforms that have successfully been used for measuring changes in phosphorylation level of drug targets and downstream substrates using clinical specimens and the strengths and weaknesses of the different platforms.
The Role of Proteomics in the Diagnosis and Treatment of Women's Cancers: Current Trends in Technology and Future Opportunities
Six of the latest techniques to understand proteomics in cancer are discussed and research utilizing these techniques are highlighted with the goal of improvement in the management of women's cancers.
Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer
Progress is being made in identifying protein biomarker signatures of clinical utility, using blood-based proteomics, using single to multiplex biomarkers that can provide significantly increased diagnostic accuracy.
Differential proteomics in the search for biomarkers of radiotherapy resistance
The body of work in this field where comparative proteomics methods have been used for the discovery of putative biomarkers associated with radiotherapy resistance is described and the reader is informed on the current status of proteomics-based findings.
Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer
A comprehensive biomarker pathway that extends from discovery through to validation on a TMA platform is developed and resulted in the identification of a novel 3-protein prognostic panel for breast cancer.
Emerging power of proteomics for delineation of intrinsic tumor subtypes and resistance mechanisms to anti-cancer therapies
This work reviews recent advances in quantitative proteomic technology and their applications in studies to identify intrinsic tumor subtypes of various tumors, to illuminate mechanistic aspects of pharmacological and oncogenic adaptations, and to highlight interaction targets for anti-cancer compounds and cancer-addicted proteins.


Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer.
The role of DNA microarrays and tissuemicroarrays in the validation of biomarkers in breast cancer is reviewed, with emphasis on their potential application to determine mode of personalised therapy in the future.
Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts.
A rapid screen to monitor PD responses within xenografted human tumors as an important step towards a clinically applicable technology is developed and optimized of the Meso Scale Discovery (MSD) platform.
High-throughput proteomics using antibody microarrays: an update
This review describes an update of high-throughput proteomics, using antibody-based microarrays, focusing on key technological advances and novel applications that have emerged over the last 3 years.
Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays.
Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer
The type and quality of evidence that has been gathered to date to predict resistance to monoclonal antibodies against EGFR in CRC is reviewed, with a focus on KRAS.
Clinical proteomics: translating benchside promise into bedside reality
Proteomic technologies that are being developed to detect cancer earlier, to discover the next generation of targets and imaging biomarkers, and finally to tailor the therapy to the patient are described.
Antibody-Based Profiling of the Phosphoinositide 3-Kinase Pathway in Clinical Prostate Cancer
It is shown that loss of PTEN is highly correlated with the activation of AKT, and this, in turn, is associated with the phosphorylation of S6, one of its main effectors.
A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers.
This review will focus on the faults of TMAs and the challenges of TMA studies that have been overcome in the last decade, and the role ofTMAs in the latest revolution in cancer treatment, the use of targeted drug therapy.
A strategy for discovery of cancer glyco‐biomarkers in serum using newly developed technologies for glycoproteomics
This paper has identified many glycoproteins containing glycan structures that are altered in cancer cells using a quantitative real‐time PCR array for glycogenes and an isotope‐coded glycosylation site‐specific tagging high‐throughput method to identify carrier proteins with the specific lectin epitope.
Antibody-based tissue profiling as a tool for clinical proteomics
The data presented here suggest that antibody-based profiling of protein expression in tissues can be used as a valuable tool in clinical proteomics.